VANCOUVER, British Columbia--(BUSINESS WIRE)--Contextual Genomics, developers of genomics-based cancer tests, is pleased to announce a scientific collaboration with the NCIC Clinical Trials Group (NCIC CTG) to research gene mutations in cancer.
As part of the collaboration, NCIC CTG will use Contextual’s genomics-based cancer tests to determine the cancer mutations present in patients in a Phase 2 clinical trial conducted by NCIC CTG. Contextual Genomics’ CG001 Hotspot Cancer Panel focuses on known mutations in solid tumour cancers most of which are treatable with current therapies or Phase 3 investigational treatments. The results of the test will help identify therapeutic targets and drive a shift to personalized treatment for patients.
Help employers find you! Check out all the jobs and post your resume.
As part of the collaboration, NCIC CTG will use Contextual’s genomics-based cancer tests to determine the cancer mutations present in patients in a Phase 2 clinical trial conducted by NCIC CTG. Contextual Genomics’ CG001 Hotspot Cancer Panel focuses on known mutations in solid tumour cancers most of which are treatable with current therapies or Phase 3 investigational treatments. The results of the test will help identify therapeutic targets and drive a shift to personalized treatment for patients.
Help employers find you! Check out all the jobs and post your resume.
